Relevance of compartmentalization of T-cell subsets for clinical improvement in psoriasis: Effect of immune-targeted antipsoriatic therapies

British Journal of Dermatology

Volumn 159, Issue 1, 2008, Pages 91-96

  Van Lingen, R G ^a   Korver J E M ^a   Van De Kerkhof, P C M ^a   Berends, M A M ^a   Van Rens, D W A ^a   Langewouters, A M ^a   Boezeman, J B M ^a   Seyger, M M B ^a   De Jong, E M G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Compartmentalization; Peripheral blood; Psoriasis; Skin; T cells

Indexed keywords

ANTIPSORIASIS AGENT; CD16 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; EFALIZUMAB; ETANERCEPT; INTERLEUKIN 2 RECEPTOR ALPHA;

ADULT; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DERMIS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EPIDERMIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; LOADING DRUG DOSE; MALE; PRIORITY JOURNAL; PSORIASIS; SCORING SYSTEM; SKIN BIOPSY; T LYMPHOCYTE SUBPOPULATION;

ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; EPIDERMIS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 45749099216     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08618.x     Document Type: Article

References (15)

1. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 2006 54 : S67 80.
2. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007 445 : 866 73.
3. Gordon KB, Papp KA, Hamilton TK et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003 290 : 3073 80.
4. Leonardi CL, Papp KA, Gordon KB et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005 52 : 425 33.
5. Papp KA, Bressinck R, Fretzin S et al. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol 2006 45 : 605 14.
6. Berends MA, Driessen RJ, Langewouters AM et al. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. J Dermatolog Treat 2007 18 : 76 83.
7. Enbrel (etanercept). Full Prescribing Information [Package Insert]. Thousand Oaks, CA : Immunex Corp., 2006.
8. Gottlieb AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003 139 : 1627 32.
9. Kupper TS. Immunologic targets in psoriasis. N Engl J Med 2003 349 : 1987 90.
10. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003 349 : 2014 22.
11. Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005 152 : 1304 12.
12. Vissers WH, Arndtz CH, Muys L et al. Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br J Dermatol 2004 150 : 852 9.
13. Bovenschen HJ, Seyger MM, van de Kerkhof PC. Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation. Br J Dermatol 2005 153 : 72 8.
14. Boehncke WH, Ochsendorf FR, Noll S et al. Efficacy of the fully human monoclonal antibody MOR102 (#5) against intercellular adhesion molecule 1 in the psoriasis-severe combined immunodeficient mouse model. Br J Dermatol 2005 153 : 758 66.
15. Costanzo A, Peris K, Talamonti M et al. Long-term treatment of plaque psoriasis with efalizumab: an Italian experience. Br J Dermatol 2007 156 (Suppl. 2 17 23.